In terms of feasibility today, telomeres YES, but mutations NO. I work in that area and will say that current technology isn’t accurate enough to spot mutations in single cells which is what you’d need (it works in cancer which have clonal expansions of mutated cells and gives you better variant call confidence). Right now sequencing error rates are too high still.